Narrative
Full Description
Project narrative
On or around March 31, 2017, the Shenzhen Branch of China Construction Corporation (CCB) entered into a $20,000,000.00 USD term loan facility agreement with Hepalink USA Inc. — a United States-incorporated and based pharmaceutical company and wholly-owned subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., a Chinese multinational company dual-listed in Hong Kong and mainland China — for unspecified purposes. This loan carried a three-month LIBOR plus a margin of 1.3% and a loan period of March 13, 2017 to March 13, 2020 (a maturity period of three years). Shenzhen Hepalink Pharmaceutical Group Co., Ltd. issued a guarantee for this loan. Record ID#106054 captures the $20 million loan. On or around June 13, 2017, the Shenzhen Branch of CCB entered into a $10,000,000.00 USD term loan facility agreement with Hepalink USA Inc. for unspecified purposes. This loan carried a three-month LIBOR plus a margin of 1.3% and a loan period of June 13, 2017 to June 15, 2020 (a maturity period of three years). Shenzhen Hepalink Pharmaceutical Group Co., Ltd. issued a guarantee for this loan. Record ID#106055 captures the $10 million loan. On or around July 6, 2017, the Shenzhen Branch of CCB entered into a $27,000,000.00 USD term loan facility agreement with Hepalink USA Inc. for unspecified purposes. This loan carried a three-month LIBOR plus a margin of 1.3% and a loan period of July 6, 2017 to July 6, 2020 (a maturity period of three years). Shenzhen Hepalink Pharmaceutical Group Co., Ltd. issued a guarantee for this loan. Record ID#106056 captures the $27 million loan.
Staff comments
1. The average 3-month LIBOR for June 2017 was 1.26241%. Therefore, the interest rate has 1.26241% + 1.3% = 2.56241%.